A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Bristol-Myers Squibb (BMS)

Status and phase

Terminated

Phase 2

Conditions

Renal Cell Carcinoma

Treatments

Biological: Ipilimumab

Biological: Nivolumab

Study type

Interventional

Funder types

Industry

Identifiers

CA209-73M

Details and patient eligibility

About

The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.

Enrollment

5 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

-Participants and Target Disease Characteristics- -

Confirmed disease progression by RECIST 1.1 criteria on nivolumab maintenance after induction with ipilimumab and nivolumab
Progress of maintenance treatment of nivolumab by RECIST. Pathology report must be submitted for embedded tissue block or tumor tissue.

Age and Reproduction Sexually active males with WOCBP must agree to instructions for contraception and fetal protection.

WOCBP need to use contraception throughout the study and for 5 months post treatment.

Exclusion Criteria autoimmune disease statement

Active central nervous system metastases
Participants with an active autoimmune disease, diabetes mellitus, skin disorders, hyperthyroidism requiring hormone treatments are permitted to enroll.
Any major surgery 28 days before 1st treatment Concomitant Therapy
participants that have received a live vaccine within 30 days of treatment.
use of investigational agent or device with in 28 days before first dosage study treatment.

Physical and Laboratory Test Findings Allergies and Adverse Drug Reaction Age and Reproduction